Your session is about to expire
← Back to Search
XL114 for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing a new cancer drug, XL114, to see if it is safe and effective. The study will also help determine the best dose of the drug.
- Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma
- Lymphoma
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the desired end-results of this experiment?
"This clinical trial aims to assess the objective response rate (ORR) of XL114 over a four-to-six month period. Secondary objectives include evaluating antitumor activity through progression free survival, overall survival duration, and tolerability as measured by dose intensity, modifications, and study discontinuation due to adverse effects."
Has XL114 attained regulatory clearance from the FDA?
"Our experts at Power rate XL114's safety as a 1, due to the limited amount of evidence currently available from this Phase 1 trial."
Does this experiment have any open positions for those seeking to participate?
"Clinicaltrials.gov confirms that this clinical trial, initially posted on April 12th 2022, is currently accepting enrolment applications. The study was last edited on September 1st of the same year."
Can you provide an estimate of the aggregate amount of people participating in this clinical investigation?
"Exelixis, the trial's sponsor, must recruit 144 eligible participants located in multiple sites including Exelixis Clinical Site #2 in Spokane, Washington and Exelixis Clinical Site #1 in Indianapolis, Indiana."
Share this study with friends
Copy Link
Messenger